Coxiella burnetii
777
C. burnetii is found in large numbers in birth fluids of goat and cows (Stoker and Marmion, 1955). Humans are then infected by inhaling from the infected aerosols or dust particles with the contaminated birth fluids. Approximately only 10 microorganisms are needed to infect humans (Tigertt et al., 1961). Based on animal models, C. burnetii is first engulfed by macrophages after inital infection in the lungs (Burton et al., 1971)(Burton et al., 1978). The microorganism grows within the acidic environment, with a pH around 4.7 - 4.8 (Ohkuma and Poole, 1978), in the phagolysosome and eventually rupture the host cells and infect other neighboring cells (Hackstadt and Williams, 1981) (Burton et al., 1971). C. burnetii suppresses the host immune responses and avoids host cell activation (avoid recognition by TLR). As a result, the microogranism is able to persist within phagolysosome (Zamboni et al., 2004)(Shannon et al., 2005).
Q fever
Antibodies produced by the immune system is not the primary mechanism used for resistance. Studies have shown that the activation of monocytes and macrophages by gamma interferon results in the production of active nitrogen and oxygen intermediates. This mechanism results in the killing of C. burnetii (Brennan et al., 2004)(Turco et al., 1984). However, C. burnetii minimizes detection by the host cell, thereby minimizes the killing by the intermediates (see Microbial Pathogensis for more information).
Several species are infected by C. burnetii. However, the disease seems to be more severe in human beings (Waag, 2007). C. burnetii has also been found to cause abortions in humans, goats, sheeps, and cattles (Langley et al., 2003)(Palmer et al., 1983)(Waldhalm et al., 1978). C. burnetii can be cultured and isolated using chicken embryo yolk sacs. Model organisms normally use for infection research include mice and guinea pigs, and sheeps (Williams and Thompson, 1991).
Coxiella burnetii is an intracellular organism that causes Q fever. Unlike other rickettisiae, however, C. burnetii, multiplies in the phagolysosomal vacuoles and remains in the vacuoles throughout its life cycle (Burton et al., 1971) (Burton et al., 1978) (Ormsbee, 1969). The microorganism is able to survive under the hostile conditions within the phagolysosomes (Akporiaye and Baca, 1983). C. burnetii also has two phases (phase I and phase II) based on the pathways involved and the cell coating (Mege et al., 1997) (Capo et al., 1999). Phase I organisms are more virulent and have complete smooth-type lipopolysaccharide (LPS) while phase II organisms are avirulent and have incomplete rough-type LPS (Hackstadt et al., 1985) . Due to highly resistance to chemical agents and hostile environments, and the low number of C. burnetii required for an infection through inhalation, Coxiella burnetii is listed CDC category B priority agent. Common symptoms for Q fever include fever, headache, malaise, and myalgia.
Baboon
Papio cynocephalus
9556
Bank vole
Clethrionomys glareolus
447135
Bear
Ursus americanus
9643
Birds
Passeroidea
175121
Brown Trout
Salmo trutta
8032
Buffalo
Bison bison
9901
Carnivores
Vulpes
9625
Cat
Felis catus
9685
Catfishes
Siluriformes
7995
Cattle
Bos taurus
9913
Chicken
Gallus gallus
9031
Chimpanzee
Pan troglodytes
9598
chinchillas
Chinchillidae
10150
Copper Pheasant
Syrmaticus soemmerringii
9067
Deer
Cervus elaphus
9860
Deer mouse
Peromyscus maniculatus
10042
Dog
Canis familiaris
9615
Ducks
Anas
8835
Ferret
Mustela putorius furo
9669
Fish
Hyperotreti
117565
Gerbil
Gerbillina
10045
Goat
Capra hircus
9925
Gray wolf
Canis lupus
9612
Guinea pig
Cavia porcellus
10141
Hamster
Mesocricetus auratus
10036
Horse
Equus caballus
9796
Human
Homo sapiens
9606
Macaque
Macaca fascicularis
9541
Mongolian Gerbil
Meriones unguiculatus
10047
Monkey
Platyrrhini
9479
Mouse
Mus musculus
10090
None
None
Parrot
Psittacidae
9224
Pig
Sus scrofa
9823
Rabbit
Oryctolagus cuniculus
9986
Rainbow trout
Oncorhynchus mykiss
8022
Rat
Rattus
10114
Raven
Corvus corax
56781
sei whale
Balaenoptera borealis
9768
Sheep
Ovis aries
9940
Squirrel
Spermophilus richardsonii
37591
Tree shrew
Tupaiidae
9393
Trouts, salmons & chars
Salmoninae
504568
Turkey
Meleagris gallopavo
9103
Vole
Microtus ochrogaster
79684
Water buffalo
Bubalus bubalis
391902
Chlamyvax FQ
Chlamyvax-FQ
VO_0004135
Inactivated or "killed" vaccine
Chlamyvax FQ is an inactivated phase II vaccine commercially available in France (Arricau-Bouvery et al., 2005).
Chlamyvax FQ is prepared as an oil emulsion with Chlamydophila abortus and phase II C. burnetii.
After the goats were vaccinated and before the challenge, the antibody response was lower in the group vaccinated with Chlamyvax FQ than the group vaccinated with phase I vaccine Coxevac. This showed that the phase II vaccine antigens were less immunogenic than phase I vaccine antigens. About 7 weeks after challenge, goats vaccinated with Chlamyvax FQ had higher antibody rates than those of goats vaccinated with Coxevac, indicating that the phase II vaccine Chlamyvax FQ was not sufficient in controlling bacterial infection (Arricau-Bouvery et al., 2005).
Two groups of goat (one- and two year-old) were immunized subcutaneously with either Chlamyvax FQ or Coxevac six weeks before mating. Three weeks after initial vaccination, a booster dose was injected. A group of unvaccinated goats served as the control (Arricau-Bouvery et al., 2005).
Chlamyvax FQ did not show effectiveness in protection against abortion and C. burnetii shedding in milk, feces, placenta, and vaginal secretions. Results showed that 87% and 93.3% of the goats vaccinated with Chlamyvax FQ had abortion and contaminated placenta, respectively. These figures were comparable with the data from the control group without vaccination (Arricau-Bouvery et al., 2005).
The groups of goats were challenged with 10^4 infective mouse doses (I.M.D.) of CbC1 strain C. burnetii 105 days after booster dose, injected subcutaneously in the front right shoulder (Arricau-Bouvery et al., 2005).
Chloroform-methanol residue (CMR)
VO_0004132
chloroform-methanol residue vaccine
The CMR vaccine consists of chloroform-methanol residues from killed whole cells of C. burnetii.
The CMR vaccine is prepared from chloroform-methanol residue of Formalin-killed whole cells of C. burnetii. C. burnetii whole cells are lyophilized and refluxed with CM azeotrope of 4:1. 150 mg of whole cells are then added to 100 ml of CM, which is then refluxed for 6 to 8 hours. Cellular material is separated by filtration and the residue on filter is mixed with 100 ml of CM. After three repetitions, the filtrate (extractable component) is the CME and the residue (particulate material) is the CMR (Williams and Cantrell, 1982).
A single 30 μg dose of CMR and a single 30 μg dose of Q-Vax resulted in similar antibody responses. The 100 μg single CMR dose and the two 30 μg doses of CMR increased the immunogenicity of the vaccine, but the antibody responses were short-lived. Anti-phases I and II antibody responses rose at equal magnitude and antibody titers leveled off 2 weeks after challenge for the vaccinated monkeys. In contrast, control monkeys had a higher anti-phase II response than anti-phase I response. Within three weeks, monkeys in control group had anti-phase II response that was greater than that in the vaccinated monkeys (Waag et al., 2002).
Adult cynomolgus monkeys
Two groups of 10 monkeys (2.0 to 6.0 kg in weight) were immunized with 30 μg of CMR subcutaneously. Single groups were immunized with 30 μg of Q-Vax, or 100 μg of CMR, or placebo subcutaneously.The group initially given 30 μg of CMR was given a booster of another 30 μg of CMR after twenty-eight days (Waag et al., 2002).
The antibody responses at single 100 μg dose of CMR and two 30 μg doses of CMR were short-lived. Anti-phases I and II antibody levels dropped to baseline levels at the 17th week after immunization (Waag et al., 2002).
The study showed that CMR and Q-Vax were equally efficacious and immunogenic in monkeys challenged by aerosol (Waag et al., 2002).
Monkeys challenged six months after vaccination showed signs of illness. However, the illnesses were less severe and/or of shorter duration for the vaccinated monkeys than for the control monkeys. A majority of the control monkeys had increases in interstitial and bronchial opacity (as opposed to only a minority of vaccinated monkeys showing those changes). A drop in hemaglobin and hematocrit was observed in all groups. All monkeys, besides groups vaccinated with single dose 100 μg CMR or two 30 μg doses of CMR, were bacteremic, which correlated with fever (Waag et al., 2002).
After six months of initial immunization, the monkeys were challenged with approximately 10^5 virulent phase I Henzerling strian C. burnetii administered using aerosol (Waag et al., 2002).
This study investigated the vaccine efficacy of CMR and Q-Vax in monkeys challenged by aerosol, which resembles the route of human infection (Waag et al., 2002).
None reported
Hartley guinea pigs
Groups of seven 250-300 g Hartley guinea pigs were vaccinated subcutaneously with 0.5 ml of 0.003, 0.03, 0.3, 3, or 30 μg of CMR. Guinea pigs in control groups were given USP saline (Waag et al., 1997).
0.003 and 0.03 μg dose did not effectively protect the pigs from infection. Guinea pigs vaccinated with 0.3, 3.0, or 30.0 μg CMR were significantly protected compared to the groups injected with USP saline (Waag et al., 1997).
None reported
Six weeks from vaccination, the guinea pigs were challenged with10-fold 50% infection dose of phase I Henzerling strain C. burnetii administered in a small particle aerosol (Waag et al., 1997)
None reported
A/J
Groups of ten six-week-old A/J strain female mice were immunized with 0.5 ml of 0.01, 0.1, or 1.0 μg of CMR. Mice in control groups were given USP saline (Waag et al., 1997).
Mice vaccinated with 0.01 or 0.1 μg of CMR were not protected. However, the 1.0 μg dose of CMR were effective in protecting the mice from infection (Waag et al., 1997).
None reported
Six weeks from vaccination, the mice were challenged with10-fold 50% infection dose of phase I Henzerling strain C. burnetii administered in a small particle aerosol (Waag et al., 1997).
High titers of phase II antibodies were detected with mice immunized with CMR.Similar detection was found for killed cells treated mice. However, there was a lower level of phase I antibodies for CMR treated mice than killed whole cells treated mice. Neither phase I nor phase II antibodies was found for mice immunized with CME (Williams and Cantrell, 1982).
C57BL/10ScN mice
Endotoxin nonresponder male mice (C57BL/10ScN, 8 to 10 weeks old) in experimental groups of 5 to 10 were given a single injection of 30 or 300 μg of killed cells, CMR, or CME (Williams and Cantrell, 1982).
Mice immunized with 30 μg of CMR resulted in higher protection (70% to 90%) than mice inoculated with killed whole cells (which was 50%). However, mice immunized with 300 μg CME had only 10% survival rate (Williams and Cantrell, 1982).
No side effects of splenomegaly, hepatomegaly, or liver necrosis were observed for mice treated with CMR or CME. However, the mice group treated with killed whole cells showed severe, life-threatening side effects (Williams and Cantrell, 1982).
Fourteen or thirty days after vaccination, the mice were challenged with 7 x 10^10 PFU of viable organisms of phase I C. burnetii Ohio strain (Williams and Cantrell, 1982).
CMR induced the greatest IgM responses. IgM responses to phase I antigen were similar while the IgM responses to phase II antigen were less frequent. IgG responses were less common to CMR, phase I, and phase II antigens (Fries et al., 1993).
Volunteers without cardiovascular, pulmonary, hepatitis, renal, or immunologic disease or without hepatitis B virus or HIV type 1 infection or without receiving any immunosuppressive medication
Human subjects were randomly assigned to receive either vaccine or placebo in a ratio of 5:2. Groups of five subjects were immunized with 30, 60, or 120 μg of CMR at one-week intervals. Twenty subjects then received 240 μg of CMR. Each group had corresponding placebo recipients in the 5:2 ratio. Subjects’ temperatures were checked on days 1, 2, 3, 7, 15, and 30 with blood specimens obtained 15, 30, 90, and 180 days after immunization. Vaccine immunogenicity were assayed with kinetic enyzme-linked immunosorbent assay (KELISA) (Fries et al., 1993).
CMR at 30 and 60 μg caused minimal side effects. Higher doses of CMR caused reactions similar to those cause by 30 μg of whole-cell vaccines. 120 μg and 240 μg dose induced local erythema in 5 (out of 15) and 8 (out of 10) recipients and subcutaneous induration in 4 (out of 15) and 7 (out of 10) recipients, respectively (Fries et al., 1993).
Subjects were not challenged (Fries et al., 1993).
CMR vaccine could be safely administered to human subjects unscreened for prior C. burnetii immunity with acceptable local reactions at 30 to 120 μg doses (Fries et al., 1993).
CMR induced the greatest serum IgM responses. IgM responses to phase I antigen were similar while the IgM responses to phase II antigen were less frequent. The group receiving 240 micrograms had significantly higher responses than the placebo group at all post immunization time points. The 120-microgram dose group approached significant difference from placebo recipients at days 30, 90, and180 post immunization ( (Fries et al., 1993).
Coxevac
Coxevax
VO_0004134
Inactivated or "killed" vaccine
Coxevac vaccine is an inactivated phase I vaccine commercially available in Slovakia (Arricau-Bouvery et al., 2005).
Coxevac vaccine is prepared with Nine Mile strain of C. burnetii in yolk sacs of pathogen-free embryonated hen eggs. The vaccine consists of purified formaldehyde inactivated phase I C. burnetii corpuscular antigens. It is standardized at 100 μg of antigens in 1 ml. The vaccine is then preserved by thiomersale (Arricau-Bouvery et al., 2005).
After the goats were vaccinated and before the challenge, the antibody response was higher in the group vaccinated with Coxevac than the group vaccinated with phase II vaccine Chlamyvax FQ. This showed that the phase I vaccine antigens were more immunogenic than phase II vaccine antigens. About 7 weeks after challenge, goats vaccinated with Coxevac had lower antibody rates than those of goats vaccinated with Chlamyvax FQ, indicating that the phase I vaccine Coxevac was more sufficient in controlling bacterial infection (Arricau-Bouvery et al., 2005).
One group of goat (one- and two year-old) were immunized subcutaneously with either Coxevac or Chlamyvax FQ six weeks before mating. Three weeks after initial vaccination, a booster dose was injected. A group of unvaccinated goats served as the control (Arricau-Bouvery et al., 2005).
Coxevac showed significant protection against abortion and C. burnetii shedding in milk, feces, placenta, and vaginal secretions. Results showed that 75% and 100% of the control goats had abortion and contaminated placenta, respectively. In comparison, only 6% and 37.5% of the goats vaccinated with Coxevac had abortion and contaminated placenta, respectively (Arricau-Bouvery et al., 2005).
The groups of goats were challenged with 10^4 infective mouse doses (I.M.D.) of CbC1 strain C. burnetii 105 days after booster dose, injected subcutaneously in the front right shoulder (Arricau-Bouvery et al., 2005).
M-44
VO_0004131
Live, attenuated vaccine
M-44 vaccine is developed from attenuated phase II M-44 strain of C. burnetii (Robinson and Hasty, 1974).
Crude rickettsial pools are produced in embryonated eggs of hens free from avian leucosis virus. The embryonated eggs are inoculated with 0.2 ml of seed stock containing 10^7.9 median infectious doses at 35C. After 6 to 7 days, the yolk sacs are collected and diluted to a 50% suspension with distilled water. The strains are then obtained through purification using alternating low-speed and high-speed centrifugations. After centrifugation, the pellet is suspended in 10% sucrose and centrifuged onto a 70% sucrose solution. The purified strains are then obtained from the surface and diluted with Snyder I buffer to result in a final titer of 10^9.5 median infectious dose per ml and freeze-dried (Robinson and Hasty, 1974).
Vaccine at high doses prevented anamnestic-type response (Robinson and Hasty, 1974).
Hartley guinea pigs
Hartley guinea pigs (250 to 350 g) were immunized intraperitoneally or subcutaneously with serial 10-fold dilutions (prepared in physiological buffered saline) of M-44 vaccine (Robinson and Hasty, 1974).
10^2 median infectious dose protected the guinea pigs from death, but did not protect the animals from febrile effects of challenge. Protections against the febrile effects of the challenge of phase I C. burnetii were observed at vaccines doses of 10^4 median infectious dose or greater. Protections against the febrile effects of the challenge of phase II C. burnetii were observed at vaccine doses of 10^3 median infectious dose or greater (Robinson and Hasty, 1974).
Guinea pigs were challenged with either phase I or phase II C. burnetii (Robinson and Hasty, 1974).
P1-HspB (fusion of protein 1 and heat-shock protein B)
VO_0004133
Subunit vaccine
Complete & incomplete Freund's adjuvant
Gene fragments encoding C. burnetii outer membrane protein 1 (P1) and heat-shock protein B (HspB) are amplified by PCR from genomic DNA extracted from C. burnetii. The amplified p1 and hspB gene fragments are purified and digested with DNA endonuclease pairs BamHI/ScaI and SacI/PstI, respectively. The genes are then ligated with pQE30 (digested with homologous enzyme pair) with T4 ligase, resulting in recombinant expression plasmids pQE30/p1 and pQE30/hspB. Plasmid pQE30/p1-hspB is constructed by ligating hspB of pQE30/hspB with p1 fragment from pQE30/p1. E.coli M15 cells are then transformed with the ligation mixtures and screened on medium containing ampicillin and kanamycin. The E. coli cells were propagated in LB medium and induced by IPTG. The resulting recombinant proteins were purified by affinity chromatography with nickel-nitrilotriacetic resin (Li et al., 2005).
Recombinant protein preparation
The primers were synthesized and the target DNA fragments were amplified by PCR from C. burnetii genomic DNA. The mixture used during amplification consisted of 0.3 M primer, 200 M deoxynucleoside triphosphate, and 0.6 U of Taq polymerase (Li et al., 2005). See preparation below for more information.
Recombinant protein preparation
The primers were synthesized and the target DNA fragments were amplified by PCR from C. burnetii genomic DNA. The mixture used during amplification consisted of 0.3 M primer, 200 M deoxynucleoside triphosphate, and 0.6 U of Taq polymerase (Li et al., 2005). See preparation below for more information.
HspB was found to be efficient in eliciting humoral immunoresponses while P1 was found to be efficient in eliciting cell-mediated immunoresponses. There was higher antibody titer for HspB-ummunized mice than that for P1-immunized mice.
BALB/c
Mice (six to eight weeks old) were immunized subcutaneously with 30 μg of purified P1, HspB, P1-HspB, or whole-cell antigen with Freund's complete adjuvant. After four weeks, the mice were then immunized intraperitoneally twice every two weeks with 15 μg of homologous antigen with Freund's incomplete adjuvant (Li et al., 2005).
P1-HspB fusion protein provided a better protection against C. burnetii than that offered by P1 or HspB alone (Li et al., 2005).
Eight weeks and ten days from after initial immunization, each group of mice was challenged with10-fold 50% infection dose of C. burnetii. After seven days, mice's spleens were removed and evaluated.
(Li et al., 2005).
Q-VAX
Q-VAX
VO_0004129
Inactivated or "killed" vaccine
Q-VAX(R) is a formalin-inactivated phase I Corxiella burnetii. This vaccine is produced and licensed in Australia. It is currently the most effective vaccine in preventing Q fever (Ackland et al., 1994).
The formalin-inactivated vaccine is prepared from phase I Henzerling strain of Corxiella burnetii grown in the yolk sacs of embryonated eggs (Ackland et al., 1994).
A single 30 μg dose of Q-Vax and a single 30 μg dose of CMR resulted in similar antibody responses. Anti-phases I and II antibody responses rose at equal magnitude and antibody titers leveled off 2 weeks after challenge for the vaccinated monkeys (for both Q-Vax and CMR). In contrast, control monkeys had a higher anti-phase II response than anti-phase I response. Within three weeks, monkeys in control group had anti-phase II response that was greater than that in the vaccinated monkeys (Waag et al., 2002).
Adult cynomolgus monkeys
Groups of 10 monkeys (2.0 to 6.0 kg in weight) were immunized with 30 μg of Q-Vax, or 100 μg of CMR, or placebo subcutaneously. Two groups were immunized with 30 μg of CMR subcutaneously. The group initially given 30 μg of CMR was given a booster of another 30 μg of CMR after twenty-eight days (Waag et al., 2002).
The study showed that CMR and Q-Vax were equally efficacious and immunogenic in monkeys challenged by aerosol (Waag et al., 2002).
Monkeys challenged six months after vaccination showed signs of illness. However, the illnesses were less severe and/or of shorter duration for the both Q-Vax and CMR vaccinated monkeys than for the control monkeys. A majority of the control monkeys had increases in interstitial and bronchial opacity (as opposed to only a minority of vaccinated monkeys showing those changes). A drop in hemaglobin and hematocrit was observed in all groups. All monkeys, besides groups vaccinated with single dose 100 μg CMR or two 30 μg doses of CMR, were bacteremic, which correlated with fever (Waag et al., 2002).
After six months of initial immunization, the monkeys were challenged with approximately 10^5 virulent phase I Henzerling strian C. burnetii administered using aerosol (Waag et al., 2002).
This study investigated the vaccine efficacy of CMR and Q-Vax in monkeys challenged by aerosol (Waag et al., 2002). See Host Response (Host Name: Monkey) under Chloroform-methanol residue (CMR) for more descriptive detail on results of the groups vaccinated with CMR.
None reported
A/J
Groups of ten six-week-old A/J strain female mice were immunized with 0.5 ml of 0.01, 0.1, or 1.0 μg of Q-Vax. Mice in control groups were given USP saline (Waag et al., 1997).
Mice vaccinated with 0.01 or 0.1 μg of Q-Vax were not protected. However, the 1.0 μg dose of Q-Vax were effective in protecting the mice from infection (Waag et al., 1997).
None reported
Six weeks from vaccination, the mice were challenged with10-fold 50% infection dose of phase I Henzerling strain C. burnetii administered in a small particle aerosol (Waag et al., 1997).
None reported
Hartley guinea pigs
Groups of seven 250-300 g Hartley guinea pigs were vaccinated subcutaneously with 0.5 ml of 0.003, 0.03, 0.3, 3, or 30 μg of Q-Vax. Guinea pigs in control groups were given USP saline (Waag et al., 1997).
0.003 and 0.03 μg dose did not effectively protect the pigs from infection. Guinea pigs vaccinated with 0.3, 3.0, or 30.0 μg Q-Vax were significantly protected compared to the groups injected with USP saline (Waag et al., 1997).
None reported
Six weeks from vaccination, the guinea pigs were challenged with10-fold 50% infection dose of phase I Henzerling strain C. burnetii administered in a small particle aerosol (Waag et al., 1997).
Among the 2555 employees who were vaccinated, only two cases of Q fever were found. However, 55 cases were found among the 1365 unvaccinated employees. The two vaccinated employees had Q fever only within days of vaccination (before immunity was developed). Therefore, the protective efficacy of Q-Vax was 100% (Ackland et al., 1994).
A survey of all vaccinated and unvaccinated employees who had Q fever at three abattoirs in Australia from 1985 to 1990 were studied (Ackland et al., 1994).
htpB
Coxiella burnetii
VO_0010934
197253489
AY251297
CDD:234573
CDD:237231
CDD:239460
777
?
heat shock protein B
4.88
51650.62
612
chaperonin GroEL; Reviewed; PRK00013
>gi|30142089|gb|AY251297.1| Coxiella burnetii strain Xinqiao heat shock protein B (htpB) gene, complete cds
ATGGCTGCAAAAGTTTTAAAATTTTCCCACGAGGTATTACACGCAATGAGTCGTGGCGTGGAAGTTTTGG
CCAACGCGGTAAAAGTGACGTTGGGACCAAAAGGTCGCAATGTCGTTTTAGATAAATCATTTGGCGCACC
AACCATTACTAAAGACGGCGTTAGCGTAGCTAAAGAAATCGAGTTGGAAGACAAATTTGAAAATATGGGC
GCTCAAATGGTTAAAGAAGTGGCTTCGCGTACATCAGACGATGCGGGTGATGGTACCACAACAGCGACCG
TACTGGCTCAAGCGATTTTGGTTGAAGGCATCAAAGCCGTTATTGCTGGAATGAACCCCATGGATTTGAA
ACGGGGTATTGATAAAGCCGTAACGGCAGCGGTAGCTGAATTGAAGAAAATTTCCAAGCCTTGCAAAGAC
CAGAAAGCGATTGCGCAAGTAGGCACCATTTCTGCGAATTCGGATAAGTCGATTGGAGATATTATTGCGG
AAGCGATGGAGAAAGTGGGCAAAGAAGGCGTCATAACAGTAGAAGATGGCTCTGGTCTTGAAAACGCGCT
TGAAGTAGTTGAAGGTATGCAGTTCGATCGTGGTTACTTGTCGCCATACTTTATCAACAATCAACAAAAC
ATGAGTGCGGAGCTTGAAAATCCGTTTATCTTATTGGTTGACAAGAAGATTTCTAATATTCGTGAACTCA
TTCCGTTGTTAGAAAACATAGCAAAGTCTGGTCGGCCCTTATTGGTGATTGCCGAAGATATCGAAGGCGA
AGCTTTAGCGACGTTAGTGGTTAATAATATTCGCGGTGTTGTTAAAGTCGCGGCTGTAAAAGCACCTGGC
TTTGGCGATCGTCGTAAAGCGATGTTGCAAGATATTGCTGTTTTGACGGGCGGTAAGGTTATTTCTGAAG
AAGTCGGATTGTCCCTTGAGGCCGCTTCTTTGGATGATTTAGGTTCTGCTAAACGCGTTGTTGTCACTAA
AGATGACACCACCATCATTGATGGTTCTGGTGACGCCGGTGACATTAAAAACCGCGTGGAGCAAATCCGA
AAAGAAATAGAAAATAGCTCGTCGGACTATGATAAAGAGAAATTACAAGAACGTCTGGCAAAATTAGCCG
GTGGTGTGGCGGTCATTAAAGTGGGCGCTGCGACTGAAGTTGAAATGAAAGAGAAAAAAGCCCGCGTGGA
AGATGCCTTACATGCGACGCGCGCAGCCGTCGAAGAAGGTGTCGTACCGGGTGGTGGCGTTGCTTTAATC
CGCGTGCTTAAATCGCTTGATTCAGTGGAAGTTGAGAATGAAGACCAACGCGTGGGCGTGGAAATTGCTC
GCCGTGCGATGGCTTACCCGCTTTCTCAAATCGTGAAAAACACGGGTGTTCAAGCAGCCGTTGTCGCTGA
CAAAGTCTTGAACCATAAAGACGTTAATTATGGTTATAACGCAGCGACGGGTGAATACGGTGACATGATT
GAGATGGGTATTCTCGACCCAACCAAAGTGACCCGCACCGCGTTGCAAAACGCAGCTTCTATCGCTGGTC
TTATGATTACCACCGAATGTATGGTAACAGAAGCTCCCAAGAAGAAAGAGGAGTCGATGCCCGGCGGCGG
TGACATGGGCGGCATGGGAGGAATGGGCGGCATGGGCGGCATGATGTAA
>ACH54112.1 heat shock protein B, partial [Coxiella burnetii]
AAKVLKFSHEVLHAMSRGVEVLADAVKVTLGPKGRNVVLDKSFGAPTITKDGVSVAKEIELEDKFENMGA
QMVKEVASRTSDDAGDGTTTATVLAQAILVEGIKAVIAGMNPMDLKRGIDKAVTAAVAELKKISKPCKDQ
KAIAQVGTISANSDKSIGDIIAEAMEKVGKEGVITVEDGSGLENALEVVEGMQFDRGYLSPYFINNQQNM
SAELENPFILLVDKKISNIRELIPLLENVAKSGRPLLVIAEDIEGEALATLVVNNIRGVVKVAAVKAPGF
GDRRKAMLQDIAVLTGGKVISEEVGLSLEAASLDDLGSAKRVVVTKDDTTIIDGSGDAGDIKNRVEQIRK
EIENSSSDYDKEKLQERLAKLAGGVAVIKVGAATEVEMKEKKARVEDALHATRAAVEEGVVPGGGVALIR
VLKSLDSVEVENEDQRVGVEIARRAMAYPLSQIVKNTGVQAAVVADKVLNHKDVNYGYNAATGEYGDMIE
MGILDPTKVTRTALQNAASIAGLMITTECMVTEAPKKKEESMPGGGDMGGM
Protective antigen
The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [Ref621:Li et al., 2005].
This result showed that these proteins had the ability to evoke a humoral immune response and yield specific antibodies whose reactivity increased gradually with the progression of the infection. In addition, 15 proteins on the array had higher FI values than the Coxiella outer membrane protein 1 (Com1), which is the first surface protein antigen of C. burnetii recognized by Q fever sera. This suggests that these proteins might be major seroreactive antigens of C. burnetii. [Ref4679:Wang et al., 2013]
IgM (partial)
Homo sapiens
1020017
CDD:143181
CDD:203725
9606
?
IgM
112
Immunoglobulin (Ig) light chain, kappa type, variable (V) domain; cd04980
>gi|1020017|gb|AAC41922.1| IgM, partial [Homo sapiens]
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTE
FTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIKRTVA
Vaximmutor
p1
Coxiella burnetii
VO_0010930
ACJ19787
AY249911
ncbi protein accession number: AAP04425.1
434924
?
outer membrane porin P1
7.87
25162.44
321
phase I
>gi|30025840|gb|AY249911.1| Coxiella burnetii strain Xinqiao outer membrane protein P1 gene, complete cds
ATGGAAACAACTACAAAACTCGCCATAGGCGTTTCTGCACTATGCTGCTTAGCCAGCGCTGCCTTTGCTG
GCGGTCCTGATATCCCCATGATTGATATGAATGGTTTTCATATCGGTTTGGGTTTTGGATATAAATCTTA
TACCTATGATCAGGTCGGAACCGTTACAGTTACTACTAATGGGGGCACTGTTCTGAGCGTGCTTCACCCA
GTTTCTGCTTCAATAACCCAATCTGGTCCTGTCGGTGAATTAGGTTATACCTTCGCAAGTGACTGGTGGA
TAGCAGGTGTTAAGGCTCAATACCAGTACGATAACGTACGAAGCGTCCACATAATGGATGCACCTTTAGT
AGGTTCTAATTATTCTTATCGAATCCGTTTGGGTTCCCACTTTACTGCTATGCTGTTAGCAGGTATTAAA
GTAAACGAAGCTAATGCTGTTTACTTAGAAGCCGGTTATTCGACAGTGTGGGGGAAAACTACCCTCTTTG
GTCCTGGCCCAGTTGCAGTTAGTATAAAGAATCGGCTGAACGGTGGTATCGCTGGTATCGGTTGGAGACA
TTATTTTATGAACAATGTCTTTCTTGATCTTAGCTATGACTACGCATTGTATAGAAGTAAATCCAATAGC
GTAACTCTCTCTTCAGCTACTGCTTCAGCAGAAGGGACGGCGATTGGCGTTTCAGGAACTGTTCAAAATC
CGAAACGAGTCGCAATTAACGGCATTACCGCAACCGTTAATTACCTGTTCAATATCTAA
>ACJ19787.1 outer membrane porin P1 [Coxiella burnetii CbuK_Q154]
METTTKLAIGVSALCCLASAAFAGGPDIPMIDMNGFHIGLGFGYKSYTYDQVGTVTVTTDGGTILSVLHP
VSASITQFSPVGELGYTFASDWWIAGVKAQYQYDNVRSVHIMDASLVGSTYRTRLGSHLTAMLLAGIKVN
EANAVYLEAGYSTVWGKTTLFGPGPVAVSMKNRLNGGIAGIGWRHYFMNNVFLDLSYDYALYRSKSNSVT
LSSATASAEEAAIGVLGTVQNPKRVAINGITATVNYLFNI
Protective antigen
The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [Ref621:Li et al., 2005].
The identification of 37 SEPs and show that 30 react with sera from mice immunized with Cox. burnetii and sera from patients with Q fever. [Ref4899:Jiao et al., 2014]
Ackland et al., 1994
journal
Ackland JR, Worswick DA, Marmion BP
Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990
1994
160
11
704-708
The Medical journal of Australia
Akporiaye and Baca, 1983
journal
Akporiaye ET, Baca OG
Superoxide anion production and superoxide dismutase and catalase activities in Coxiella burnetii
1983
154
1
520-523
Journal of bacteriology
Arricau-Bouvery et al., 2005
journal
Arricau-Bouvery N, Souriau A, Bodier C, Dufour P, Rousset E, Rodolakis A
Effect of vaccination with phase I and phase II Coxiella burnetii vaccines in pregnant goats
2005
23
35
4392-4402
Vaccine
Brennan et al., 2004
journal
Brennan RE, Russell K, Zhang G, Samuel JE
Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections
2004
72
11
6666-6675
Infection and immunity
Burton et al., 1971
journal
Burton PR, Kordova N, Paretsky D
Electron microscopic studies of the rickettsia Coxiella burneti: entry, lysosomal response, and fate of rickettsial DNA in L-cells
1971
17
2
143-150
Canadian journal of microbiology
Burton et al., 1978
journal
Burton PR, Stueckemann J, Welsh RM, Paretsky D
Some ultrastructural effects of persistent infections by the rickettsia Coxiella burnetii in mouse L cells and green monkey kidney (Vero) cells
1978
21
2
556-566
Infection and immunity
Capo et al., 1999
journal
Capo C, Lindberg FP, Meconi S, Zaffran Y, Tardei G, Brown EJ, Raoult D, Mege JL
Subversion of monocyte functions by coxiella burnetii: impairment of the cross-talk between alphavbeta3 integrin and CR3
1999
163
11
6078-6085
Journal of immunology (Baltimore, Md. : 1950)
Fries et al., 1993
journal
Fries LF, Waag DM, Williams JC
Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever
1993
61
4
1251-1258
Infection and immunity
Hackstadt and Williams, 1981
journal
Hackstadt T, Williams JC
Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii
1981
78
5
3240-3244
Proceedings of the National Academy of Sciences of the United States of America
Hackstadt et al., 1985
journal
Hackstadt T, Peacock MG, Hitchcock PJ, Cole RL
Lipopolysaccharide variation in Coxiella burnetti: intrastrain heterogeneity in structure and antigenicity
1985
48
2
359-365
Infection and immunity
Jiao et al., 2014
journal
Jiao J, Xiong X, Qi Y, Gong W, Duan C, Yang X, Wen B
Serological characterization of surface-exposed proteins of Coxiella burnetii
2014
160
Pt 12
2718-2731
Microbiology (Reading, England)
Johnson et al., 1977
journal
Johnson JW, McLeod CG, Stookey JL, Higbee GA, Pedersen CE Jr
Lesions in guinea pigs infected with Coxiella burnetii strain M-44
1977
135
6
995-998
The Journal of infectious diseases
Langley et al., 2003
journal
Langley JM, Marrie TJ, Leblanc JC, Almudevar A, Resch L, Raoult D
Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes
2003
189
1
228-232
American journal of obstetrics and gynecology
Li et al., 2005
journal
Li Q, Niu D, Wen B, Chen M, Qiu L, Zhang J
Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii
2005
1063
130-142
Annals of the New York Academy of Sciences
Mege et al., 1997
journal
Mege JL, Maurin M, Capo C, Raoult D
Coxiella burnetii: the 'query' fever bacterium. A model of immune subversion by a strictly intracellular microorganism
1997
19
4
209-217
FEMS microbiology reviews
Ohkuma and Poole, 1978
journal
Ohkuma S, Poole B
Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents
1978
75
7
3327-3331
Proceedings of the National Academy of Sciences of the United States of America
Ormsbee, 1969
journal
Ormsbee RA
Rickettsiae (as organisms)
1969
23
275-292
Annual review of microbiology
Palmer et al., 1983
journal
Palmer NC, Kierstead M, Key DW, Williams JC, Peacock MG, Vellend H
Placentitis and Abortion in Goats and Sheep in Ontario Caused by Coxiella burnetii
1983
24
2
60-61
The Canadian veterinary journal. La revue veterinaire canadienne
Robinson and Hasty, 1974
journal
Robinson DM, Hasty SE
Production of a potent vaccine from the attenuated M-44 strain of Coxiella burneti
1974
27
4
777-783
Applied microbiology
Shannon et al., 2005
journal
Shannon JG, Howe D, Heinzen RA
Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule
2005
102
24
8722-8727
Proceedings of the National Academy of Sciences of the United States of America
Stoker and Marmion, 1955
journal
Stoker MG, Marmion BP
The spread of Q fever from animals to man; the natural history of a rickettsial disease
1955
13
5
781-806
Bulletin of the World Health Organization
Tigertt et al., 1961
journal
Tigertt WD, Beneson AS, Gochenour WS
Airborne Q fever
1961
25
285-293
Bacteriological reviews
Turco et al., 1984
journal
Turco J, Thompson HA, Winkler HH
Interferon-gamma inhibits growth of Coxiella burnetii in mouse fibroblasts
1984
45
3
781-783
Infection and immunity
Waag et al., 1997
journal
Waag DM, England MJ, Pitt ML
Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol
1997
15
16
1779-1783
Vaccine
Waag et al., 2002
journal
Waag DM, England MJ, Tammariello RF, Byrne WR, Gibbs P, Banfield CM, Pitt ML
Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol
2002
20
19-20
2623-2634
Vaccine
Waag, 2007
journal
Waag DM
Coxiella burnetii: Host and bacterial responses to infection
2007
25
42
7288-7295
Vaccine
Waldhalm et al., 1978
journal
Waldhalm DG, Stoenner HG, Simmons RE, Thomas LA
Abortion associated with Coxiella burnetii infection in dairy goats
1978
173
12
1580-1581
Journal of the American Veterinary Medical Association
Wang et al., 2013
journal
Wang X, Xiong X, Graves S, Stenos J, Wen B
Protein array of Coxiella burnetii probed with Q fever sera
2013
56
5
453-459
Science China. Life sciences
Williams and Cantrell, 1982
journal
Williams JC, Cantrell JL
Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice
1982
35
3
1091-1102
Infection and immunity
Williams and Thompson, 1991
book
Williams JC, Thompson HA
Methods for isolation, amplification, and purification of Coxiella burnetii
1991
73-115
Q Fever: The Biology of Coxiella burnetii
CRC Press
Williams et al., 1990
journal
Williams JC, Hoover TA, Waag DM, Banerjee-Bhatnagar N, Bolt CR, Scott GH
Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever
1990
590
370-380
Annals of the New York Academy of Sciences
Xiong et al., 2014
journal
Xiong X, Qi Y, Jiao J, Gong W, Duan C, Wen B
Exploratory study on Th1 epitope-induced protective immunity against Coxiella burnetii infection
2014
9
1
e87206
PloS one
Zamboni et al., 2004
journal
Zamboni DS, Campos MA, Torrecilhas AC, Kiss K, Samuel JE, Golenbock DT, Lauw FN, Roy CR, Almeida IC, Gazzinelli RT
Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection
2004
279
52
54405-54415
The Journal of biological chemistry